1. Home
  2. GKOS vs MTRN Comparison

GKOS vs MTRN Comparison

Compare GKOS & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$146.06

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Materion Corporation

MTRN

Materion Corporation

HOLD

Current Price

$261.98

Market Cap

5.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
MTRN
Founded
1998
1931
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.5B
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
GKOS
MTRN
Price
$146.06
$261.98
Analyst Decision
Strong Buy
Buy
Analyst Count
12
4
Target Price
$126.92
$52.50
AVG Volume (30 Days)
928.7K
372.1K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
N/A
0.32%
EPS Growth
N/A
1178.57
EPS
N/A
0.92
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.32
$15.31
Revenue Next Year
$27.43
$7.57
P/E Ratio
N/A
$288.35
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$80.69
52 Week High
$148.62
$298.87

Technical Indicators

Market Signals
Indicator
GKOS
MTRN
Relative Strength Index (RSI) 67.05 56.01
Support Level $96.44 $119.80
Resistance Level N/A N/A
Average True Range (ATR) 5.65 13.81
MACD 1.60 -0.43
Stochastic Oscillator 98.92 38.46

Price Performance

Historical Comparison
GKOS
MTRN

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MTRN Materion Corporation

Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.

Share on Social Networks: